Real time coverage of developments and trends in health care
It is possible that you used an outdated or expired MedicineNet link or typed the address incorrectly.
Please try searching using the search field at the top of the page. If you’re not sure of the spelling, type the first few letters, followed by an asterisk(*).
To help you find what you are looking for, these links may help.
Media Advisory Wednesday, July 3, 2024 Study with 1,800 first-time moms found no added […]
Media Advisory Tuesday, September 24, 2024 What Cancer incidence trends in 2021 largely returned to […]
Early HIV treatment is a win-win strategy. David Smart/ShutterstockStarting HIV treatment early, before immune damage occurs, brings real clinical benefits, a new study has shown. The START (Strategic Timing of antiRetroviral Treatment) clinical trial was recently terminated ahead of schedule because the trial results provided conclusive evidence of the extra benefits of beginning antiretroviral therapy early. Measuring immune function The question of when to start anti-HIV treatment is of great clinical and public health significance. In the late 1990s, scientists established that antiretroviral therapy was life-saving. But untreated HIV infection takes many years to cause serious illness, so it was reasonable to consider whether delayed treatment might work as well as early treatment in preventing illness and death. Untreated HIV invades cells in